Treatment of moderate to severe pediatric asthma

Annals of Allergy, Asthma & Immunology

July 2016 Vol. 117, Issue 1, p17–20

Overall Purpose:
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:

Lakiea S. Wright, MD, MAT, MPH (Author)

Wanda Phipatanakul, MD, MS (Author)

Jonathan A. Bernstein, MD (Annals CME Subcommittee)

Guha Krishnaswamy, MD (Annals CME Subcommittee)

John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)

Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)

Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the indications for use of omalizumab in pediatric asthma
  • Discuss the evidence that supports the use of omalizumab in pediatric asthma
  • Review the literature on monoclonal antibodies that are under investigation in clinical trials for treatment of pediatric asthma R
Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Children’s Hospital of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, Health Resources and Services Administration (HRSA) and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. G. Krishnaswamy has received research grant CSL Behring. J.A. Bernstein, L.S. Wright and W. Phipatanakul have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
07/01/2016
Course expires: 
06/30/2018
Cost:
$0.00

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
07/01/2016
Course expires: 
06/30/2018

Price

Cost:
$0.00
Please login or create an account to take this course.